1315 Capital II, L.P. - Oct 11, 2024 Form 4 Insider Report for INTERPACE BIOSCIENCES, INC. (IDXG)

Role: 10%+ Owner
Signature: By 1315 Capital Management II, LLC, its sole general partner, By: Adele C. Oliva, Managing Member /s/ Adele C. Oliva
Stock symbol: IDXG
Transactions as of: Oct 11, 2024
Transactions value $: $0
Form type: 4
Date filed: 10/15/2024, 07:00 PM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IDXG	Series B Convertible Preferred Stock	Disposed to Issuer		+19K			0	Oct 11, 2024	Common Stock	3.17M	$6.00	See Footnotes	F1, F2, F3, F4
transaction	IDXG	Series C Convertible Preferred Stock	Award		+19K			19K	Oct 11, 2024	Common Stock	9.41M	$2.02	See Footnotes	F2, F3, F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares of Series B Convertible Preferred Stock, par value $0.01 per share, of the Issuer (the "Series B Preferred Shares") were convertible from time to time, at the option of the holder thereof, into a number of shares of common stock, par value $0.01 per share, of the Issuer (the "Common Stock"), equal to the initial stated value per Series B Preferred Share of $1,000 divided by a conversion price of $6.00 per share (the "Series B Conversion Price") and then multiplied by the number of Series B Preferred Shares to be converted. The Series B Preferred Shares had no expiration date.
F2	On October 11, 2024, the Issuer exchanged all 19,000 existing shares of Series B Shares held by 1315 Capital II, L.P. (the "Investor") for 19,000 newly created shares of Series C Convertible Preferred Stock, par value $0.01 per share, of the Issuer (the "Series C Preferred Shares").
F3	These securities are held of record by the Investor. 1315 Capital Management II, LLC ("1315 Capital Management") is the general partner of the Investor. By virtue of such relationship, 1315 Capital Management may be deemed to have voting and investment power with respect to the securities held by the Investor noted above and as a result may be deemed to have beneficial ownership over such securities.
F4	Each of the Investor and 1315 Capital Management disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F5	The Series C Preferred Shares are convertible from time to time, at the option of the holder thereof, into a number of shares of Common Stock equal to the initial stated value per Series C Share of $1,000 divided by an initial conversion price of $2.02 per share and then multiplied by the number of Series C Preferred Shares to be converted. The Series C Preferred Shares have no expiration date.